News Image

Exploring NASDAQ:AMPH's growth characteristics.

By Mill Chart

Last update: May 15, 2024

Growth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) is suited for growth investing. Investors should of course do their own research, but we spotted AMPHASTAR PHARMACEUTICALS IN showing up in our Louis Navellier growth screen, so it may be worth spending some more time on it.

What matters for growth investors.

  • AMPHASTAR PHARMACEUTICALS IN demonstrates a strong Return on Equity(ROE) of 23.0%. This indicates the company's ability to generate favorable returns for shareholders and reflects its efficient utilization of capital. AMPHASTAR PHARMACEUTICALS IN shows promising potential for continued success.
  • AMPHASTAR PHARMACEUTICALS IN has surpassed EPS estimates 3 times in the last 4 quarters, reflecting its strong financial performance and effective management. This trend suggests the company's ability to generate positive earnings surprises and drive shareholder value.
  • AMPHASTAR PHARMACEUTICALS IN has achieved significant 1-year revenue growth of 30.4%, signaling its ability to capture market opportunities and drive top-line expansion. This growth indicates the company's effective execution and its potential for continued success.
  • The q2q revenue growth of 22.74% of AMPHASTAR PHARMACEUTICALS IN highlights the company's ability to generate incremental revenue and suggests positive market demand for its products or services.
  • The operating margin of AMPHASTAR PHARMACEUTICALS IN has seen steady growth over the past year, signaling improved profitability. This trend indicates the company's effective cost management and its ability to generate higher returns.
  • AMPHASTAR PHARMACEUTICALS IN has shown positive growth in its free cash flow (FCF) over the past year, indicating improved cash generation and financial strength. This growth highlights the company's ability to effectively manage its cash flows and generate surplus funds.
  • AMPHASTAR PHARMACEUTICALS IN has demonstrated consistent growth in its earnings per share (EPS) from one quarter to another (Q2Q), with a 67.74% increase. This indicates improving financial performance and the company's effective management of its operations.
  • AMPHASTAR PHARMACEUTICALS IN has seen a 14.33% change in the average next Quarter EPS Estimate by analysts over the last 3 months, signaling the shifting perception of the company's EPS outlook.
  • In the most recent financial report, AMPHASTAR PHARMACEUTICALS IN reported a 67.74% increase in quarterly earnings compared to the previous quarter. This notable growth indicates positive momentum in the company's financials, suggesting an upward trend
  • accelerating EPS growth for AMPHASTAR PHARMACEUTICALS IN: the current Q2Q growth of 67.74% exceeds the previous year Q2Q growth of 31.91%.

What else is there to say on the fundamentals of NASDAQ:AMPH?

Every day, ChartMill assigns a Fundamental Rating to each stock, providing a score ranging from 0 to 10. This rating is determined by evaluating various fundamental indicators and properties.

Overall AMPH gets a fundamental rating of 6 out of 10. We evaluated AMPH against 197 industry peers in the Pharmaceuticals industry. While AMPH has a great profitability rating, there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on AMPH. This makes AMPH very considerable for value investing!

Our latest full fundamental report of AMPH contains the most current fundamental analsysis.

More ideas for growth investing can be found on ChartMill in our Lois Navellier screen.

Disclaimer

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

AMPHASTAR PHARMACEUTICALS IN

NASDAQ:AMPH (5/29/2024, 7:00:00 PM)

After market: 41.64 0 (0%)

41.64

-0.34 (-0.8%)

AMPH News

News Image14 days ago - InvestorPlacePatent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade

The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.

News Image15 days ago - ChartmillExploring NASDAQ:AMPH's growth characteristics.

AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) showing high EPS and FCF growth while beating expectations

News Image21 days ago - InvestorPlaceAMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024

AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

News Image21 days ago - BusinessInsiderAMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amphastar Pharma (NASDAQ:AMPH) just reported results for the first quarter of 2...

News Imagea month ago - Market News VideoOversold Conditions For Amphastar Pharmaceuticals (AMPH)
News Image2 months ago - Market News VideoCommit To Buy Amphastar Pharmaceuticals At $22.50, Earn 18.5% Annualized Using Options
News Image3 months ago - Market News VideoAmphastar Pharmaceuticals Becomes Oversold (AMPH)
News Image3 months ago - Market News VideoAmphastar Pharmaceuticals (AMPH) Shares Cross Below 200 DMA
News Image3 months ago - Seeking AlphaAmphastar Pharmaceuticals Non-GAAP EPS of $0.88 misses by $0.03, revenue of $178.1M beats by $4.77M (NASDAQ:AMPH)

Amphastar Pharmaceuticals reports Q4 financial results with a Non-GAAP EPS of $0.88, missing estimates by $0.03, while revenue of $178.1M beats expectations...

News Image4 months ago - Investor's Business DailyCRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+

CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

News Image4 months ago - Market News VideoAMPH Crosses Below Key Moving Average Level
News Image4 months ago - InvestorPlace3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential

As the new business cycle gets started, here are some biotech stocks with potential that investors should pay attention to.

AMPH Links
Follow us for more